drugset
drugset / Trial / NCT04736134

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

NCT04736134 ↗

Phase 1 Completed 88 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, drug effects, and immunogenicity of BMS-986326 after infusion or injection in healthy participants. The results of this study will guide the selection of the dose range, dosing frequency, and the route of administration for future studies of BMS-986326 in participants with immune-mediated diseases.

Timeline

Start
2021-03-03
Primary completion
2024-03-14
Completion
2024-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986326 Unknown — Intravenous

Indications

No indication recorded.